Skyway Capital Markets has added Wes Chapman to its advisory board.

Chapman was previously president and CEO of Verdi Oncology, a medical oncology company dedicated to value-based cancer care, which he founded in 2016.

Prior to Verdi, Chapman was an operating partner at Pharos Capital, a private equity group located in Nashville, Tennessee, with over $1.1 billion in assets under management. In addition, he served as SVP of strategy at Tennessee Oncology, as chairman and CEO of M2S Inc., and as a partner at the investment banking firms of Oppenheimer & Co. and Donaldson, Lufkin & Jenrette.

“We are honored to have Wes serve on our advisory board, and we look forward to his valuable strategic advice as we continue to grow our Healthcare practice,” remarked Skyway CEO Russ Hunt.